ARTL
What one share of Artelo Biosciences holds
Pharmaceutical Preparations
We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.
Artelo Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.38 |
|---|---|
| Cash and investments | $6.24 |
| Book value | $7.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$339.00 | — | −$316.60 | — | $209.60 |
| 2021 | — | −$107.52 | — | −$88.78 | — | $132.56 |
| 2023 | — | −$56.49 | — | −$49.91 | — | $66.33 |
| 2024 | — | −$54.89 | — | −$46.65 | — | $15.10 |
| 2025 | — | −$37.55 | — | −$24.84 | — | −$1.89 |